TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Study Supports Cost-effectiveness of Renal Denervation for …
WEBAug 23, 2024 · The overall cost-effectiveness of the procedure was relatively consistent across a variety of scenarios and sensitivity analyses. For example, ICERs ranged from $33,040 to $70,846 per QALY for patients ages 45 to 80 years, and from $31,884 to $41,524 per QALY for baseline office systolic BPs ranging from 140 to 175 mm Hg.
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the ICU (28% vs 13%; P = 0.038). …
New BedMed Data Confirm Antihypertensives Can Be Taken Any …
WEBAug 31, 2024 · The 2024 ESC guidelines for hypertension, released this week, emphasize convenience over timing. “Current evidence does not show benefit of diurnal timing of BP-lowering drug administration on major CVD outcomes,” the document notes. “It is important that medication is taken at the most convenient time of day to improve adherence.
As US Rollout Begins for Coronary DCBs, Interventionalists Mull ...
WEBMay 3, 2024 · Following the US approval of the Agent paclitaxel-coated balloon for the treatment of in-stent restenosis (ISR), the first coronary procedures with the device were performed Tuesday morning at two centers in the Northeast as Boston Scientific continues its rollout. Although drug-coated balloons (DCB) have been used for coronary …
Latest Statin Risk-Benefit Analysis: More Harm Than Good?
WEBJul 15, 2021 · (UPDATED) A new study seeking to allay concerns about statin side effects in primary prevention may have the unintended effect of reopening a debate that many physicians have long considered as settled, a prominent cardiologist warns. The stated aim of the meta-analysis, published in the BMJ, is to assess the benefit-to-harm ratio of the …
New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides
WEBAug 21, 2019 · For managing hypertriglyceridemia (200-499 mg/dL), the AHA experts state that prescription-strength omega-3 fatty acids, either with eicosapentaenoic acid (EPA) or EPA plus docosapentaenoic acid (DHA), would be expected to yield a 20% to 30% reduction in triglycerides without any increase in LDL cholesterol.
TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With …
WEBOct 26, 2023 · The study was simultaneously published in the Journal of the American College of Cardiology. QoL Endpoints. For the study, researchers looked at the first 350 patients with severe TR randomized in TRILUMINATE to tricuspid TEER (n = 175) or medical therapy (n = 175). At 1 month, patients treated with TEER saw significantly …